Amplia Therapeutics Ltd. (INNMF)

[BC239]

You're right. The 2B trial ends toward end of April. Since earlier PR indicated the vast majority of patients were asking to stay on the drug after their trial, I assume a similar PR will come out once the 2B is done.
Abstracts from Innate studies will be presented next month at a Neurology conference in Boston. Very good exposure to the scientific/medical world. I wouldn't be a bit surprised if the CEO goes to meet with pharma people. At least I hope he goes. Seems like a good forum to rub elbows with prospective buyers.